ProQR Therapeutics Correlations

PRQR Stock

USD 3.67 0.23 6.69%

The current 90-days correlation between ProQR Therapeutics and Annexon is 0.09 (i.e., Significant diversification). The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

ProQR Therapeutics Correlation With Market

Average diversification

The correlation between ProQR Therapeutics BV and DJI is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ProQR Therapeutics BV and DJI in the same portfolio, assuming nothing else is changed.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

Moving together with ProQR Stock

0.75	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.75	NAMS	NewAmsterdam Pharma	Pair Corr
0.69	PHVS	Pharvaris BV	Pair Corr
0.73	PLRX	Pliant Therapeutics	Pair Corr
0.8	PMVP	Pmv Pharmaceuticals	Pair Corr
0.77	SGMO	Sangamo Therapeutics Buyout Trend	Pair Corr
0.84	AVTE	Aerovate Therapeutics	Pair Corr
0.87	CRVS	Corvus Pharmaceuticals	Pair Corr
0.73	VREX	Varex Imaging Corp	Pair Corr

Moving against ProQR Stock

0.83	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.73	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.72	FDMT	4D Molecular Therapeutics	Pair Corr
0.71	PEPG	PepGen	Pair Corr
0.59	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.47	RGNX	Regenxbio	Pair Corr
0.44	PDSB	PDS Biotechnology Corp	Pair Corr
0.38	INKT	Mink Therapeutics	Pair Corr
0.36	IVVD	Invivyd	Pair Corr
0.36	MREO	Mereo BioPharma Group	Pair Corr
0.74	ADAP	Adaptimmune Therapeutics	Pair Corr
0.73	BDTX	Black Diamond Therap	Pair Corr
0.7	COLL	Collegium Pharmaceutical	Pair Corr
0.56	ANEB	Anebulo Pharmaceuticals	Pair Corr
0.53	SYBX	Synlogic	Pair Corr
0.43	ACIU	AC Immune	Pair Corr
0.33	STOK	Stoke Therapeutics	Pair Corr
0.31	APTO	Aptose Biosciences	Pair Corr

Related Correlations Analysis

	ANNX	ARWR	DAWN	TERN	ALNY	WVE	BPMC	APLS	ASMB	SPRO
ANNX		-0.15	0.61	0.19	0.76	0.23	-0.35	-0.37	0.61	0.2	ANNX
ARWR	-0.15		0.24	0.1	0.02	-0.17	0.31	0.68	0.33	0.38	ARWR
DAWN	0.61	0.24		0.03	0.49	0.42	0.27	-0.2	0.4	0.18	DAWN
TERN	0.19	0.1	0.03		0.2	-0.72	-0.31	0.48	0.33	0.63	TERN
ALNY	0.76	0.02	0.49	0.2		0.11	-0.33	-0.27	0.37	0.24	ALNY
WVE	0.23	-0.17	0.42	-0.72	0.11		0.24	-0.68	-0.07	-0.58	WVE
BPMC	-0.35	0.31	0.27	-0.31	-0.33	0.24		0.04	-0.22	-0.1	BPMC
APLS	-0.37	0.68	-0.2	0.48	-0.27	-0.68	0.04		0.23	0.51	APLS
ASMB	0.61	0.33	0.4	0.33	0.37	-0.07	-0.22	0.23		0.28	ASMB
SPRO	0.2	0.38	0.18	0.63	0.24	-0.58	-0.1	0.51	0.28		SPRO
	ANNX	ARWR	DAWN	TERN	ALNY	WVE	BPMC	APLS	ASMB	SPRO

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

ALNY	+ 0.76	ANNX
APLS	+ 0.68	ARWR
SPRO	+ 0.63	TERN
DAWN	+ 0.61	ANNX
ASMB	+ 0.61	ANNX
SPRO	+ 0.51	APLS

High negative correlations

WVE	- 0.72	TERN
APLS	- 0.68	WVE
SPRO	- 0.58	WVE
APLS	- 0.37	ANNX
BPMC	- 0.35	ANNX
BPMC	- 0.33	ALNY

Risk-Adjusted Indicators

There is a big difference between ProQR Stock performing well and ProQR Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ProQR Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
ANNX	2.57	(0.34)	0.00	(0.08)	0.00	0.00	6.98	(5.26)	23.00
ARWR	2.71	0.05	0.03	0.15	3.15	(3.11)	6.14	(3.86)	19.44
DAWN	2.05	(0.11)	0.00	(0.02)	0.00	0.00	3.84	(3.69)	11.44
TERN	3.39	(0.35)	0.00	(0.23)	0.00	0.00	6.02	(5.96)	34.09
ALNY	1.63	(0.29)	0.00	(0.10)	0.00	0.00	2.85	(3.88)	13.26
WVE	5.79	1.61	0.48	0.57	3.09	(8.46)	10.86	(6.00)	82.93
BPMC	1.81	(0.09)	(0.02)	0.04	2.58	(1.72)	4.90	(3.62)	14.28
APLS	2.51	(0.25)	0.00	(0.26)	0.00	0.00	4.48	(5.17)	15.97
ASMB	2.95	0.10	0.00	0.47	4.39	(2.92)	8.79	(5.34)	21.34
SPRO	1.78	(0.33)	0.00	(0.44)	0.00	0.00	3.79	(4.58)	14.92

ProQR Therapeutics Corporate Management

Aniz MD	Chief Officer	Profile
Domenico Valerio	Founder Board	Profile
Sarah Kiely	Vice Communications	Profile
Rene Beukema	Chief Corporate Devel. Officer, General Counsel, Corporate Secretary and Member of Management Board	Profile
Sheila Sponselee	VP Operations	Profile
Gerard Platenburg	Chief Innovation Officer	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC